Cipla Ltd.

CIPLA

₹1455.2

-0.94% (-13.8)

Market Cap

₹1,18,663 Cr.

P/E

26.52

About

Cipla Limited, a global pharmaceutical company established in 1935, is dedicated to providing affordable medicines to those in need. The company manufactures, develops, and markets a wide range of bra… Read more

Cipla Limited, a global pharmaceutical company established in 1935, is dedicated to providing … Read more

Low

1192

52W Range

High

1702

Timeline

Key company specific updates

Company Timeline

Subscribe now for more updates

Custom financial statementNew

Edit rows

Forensics

12 Yes

Positive for this company

2 Neutral

Neutral for this company

3 No

Negative for this company

0 No Data

Insufficient data to analyse

Accounting & Shareholding

Contingent Liabilities

Company does not have significant contingent liabilities
Depreciation Effect

Depreciation accounting is not leading to increase in profits
Other Income

Other income is not affecting ratios of the company
Pledge

Promoters have not pledged a significant portion of their holding
Retail Holding

Retail has been selling the stock which is usually a good time to buy
Promoter Holding

Promoter has not sold any shares in the last 90 days
Revenue Recognition

Chances of aggressive revenue recognition - operating profit of company is not getting converted to cash and recievables rising faster than sales

Price & Performance

Capex vs ROCE

Roce of the company has increased over the last three years
ROE

Net profit margin is responsible for roe increase over last 10 years
Share price

Share price has increased over last 10 years due to earnings
Working Capital

Working capital of the company seems to be under control
Current vs Historic Valuation

Company is trading at a discount to 3yr historic valuations
Debt

Company should not have issues servicing its debt
ROCE Strength

Roce of the company is consistently strong
Balance Sheet Strength

Balance sheet of the company is strong. but it might have issues paying it suppliers
Sales Growth

Sales of the company has grown at a slow pace
Margin Stability

Margins of the company are volatile

Market Share

1.36 %

(as of Jul 22)

Historic

Anti - Diabetes - Market Share

7.76 %

(as of Jul 22)

Historic

Anti-Infectives - Market Share

0.96 %

(as of Nov 21)

Historic

Anti-Malarial - Market Share

5.93 %

(as of Nov 21)

Historic

Antineo Plastic - Market Share

0.79 %

(as of Nov 21)

Historic

Blood Related - Market Share

4.48 %

(as of Jul 22)

Historic

Cardiovascular - Market Share

2.19 %

(as of Nov 21)

Historic

Dermatology - Market Share

0.55 %

(as of Nov 21)

Historic

Endocrinology - Market Share

2.37 %

(as of Jul 22)

Historic

Gastro-Intestinal - Market Share

1.85 %

(as of Nov 21)

Historic

Gynecology - Market Share

2.97 %

(as of Nov 21)

Historic

Neurological - Market Share

8.92 %

(as of Nov 21)

Historic

Ophthalmology - Market Share

1.94 %

(as of Nov 21)

Historic

Pain - Market Share

5.30 %

(as of Dec 22)

Historic

Pharmaceutical Sector - Market Share

23.76 %

(as of Nov 21)

Historic

Respiratory - Market Share

4.31 %

(as of Jul 22)

Historic

Sex Stimulants - Market Share

0.07 %

(as of Oct 19)

Historic

Stomatological - Market Share

18.51 %

(as of Nov 21)

Historic

Urology - Market Share

0.06 %

(as of Jul 22)

Historic

Vaccines - Market Share

0.62 %

(as of Jul 22)

Historic

Vitamin & Dietary Supplements - Market Share

Revenue mix

Product Wise Break-Up

Therapeutic Area Wise Break-Up - Domestic

Location Wise Break-Up - Global API

Location Wise Break-Up

Therapeutic Area Break-Up - Global API

Operating Profit Break-Up

Asset Break-Up

Operational Metrics

US DMF Filings (.)
Source
Number of ANDA's Filed in USA (.)
Source
Number of ANDA's Approved By USFDA (.)
Source
Domestic Sales Growth - YoY (%)
Source
R&D as a % of Total Sales (%)
Source

Peer Comparison

Brands

Bronco cough syrup

Coryx

Suppliers

Bharat Dynamics Ltd.
Laurus Labs Ltd.
Atul Ltd.
Aarti Industries Ltd.
Ion Exchange (India) Ltd.
Shakti Pumps (India) Ltd.
EPL Ltd.
Borosil Renewables Ltd.
GMM Pfaudler Ltd.
Cigniti Technologies Ltd.
Marine Electricals (India) Ltd.
Aarti Drugs Ltd.
TCI Express Ltd.
Venus Pipes & Tubes Ltd.
Vidhi Specialty Food Ingredients Ltd.
IOL Chemicals And Pharmaceuticals Ltd.
Allcargo Gati Ltd.
Control Print Ltd.
Gulshan Polyols Ltd.
Empire Industries Ltd.
Hitech Corporation Ltd.
A2Z Infra Engineering Ltd.
Take Solutions Ltd.
Mitsu Chem Plast Ltd.
Arshiya Ltd.
Vivimed Labs Ltd.

Showing 5 of 26

FAQs on Cipla Ltd. Business

What does Cipla do?

Cipla Limited is a global pharmaceutical company founded in 1935, dedicated to providing affordable medicines worldwide. It offers a broad portfolio of branded and generic formulations and APIs across multiple therapeutic segments.

Who are the competitors of Cipla?

Cipla major competitors are Torrent Pharma, Mankind Pharma, Dr. Reddy's Lab, Zydus Lifesciences, Lupin, Aurobindo Pharma, Alkem Laboratories.
Market Cap of Cipla is ₹1,23,920 Crs.
While the median market cap of its peers are ₹97,217 Crs.

Is Cipla financially stable compared to its competitors?

Cipla seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

View FAQ's On Shareprice

Cash Flow Machines

Actual Cash profits are more important than accounting profits. List of companies spitting out cash profits

Run Query

Company Filing

	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Investor Presentation	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Conference Call	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Conference Call SummaryCon Call Summary Powered by OpenAI	Dec			Mar Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec